Physician profile
Sandra Ilene Sperling
NPI 1629013545
$8,346.82
in general payments reported to CMS, 2019-2025
30 companies · $1,489 in 2025
The $1,489 reported for 2025 was more than what 85% of Psychiatric/Mental Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $244).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $459 · 2022: $2,370 · 2023: $2,227 · 2024: $1,802 · 2025: $1,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,518.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,880.25 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $880.52 | 2022-2024 | Caplyta |
| Axsome Therapeutics, INC. | $776.82 | 2022-2025 | Auvelity, Sunosi |
| Tris Pharma INC | $479.91 | 2021-2025 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $455.81 | 2021-2024 | Uzedy, Austedo Xr, Austedo |
| Lundbeck LLC | $409.64 | 2021-2025 | Rexulti, Abilify Maintena |
| Corium, LLC | $405.60 | 2021-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $404.42 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $382.04 | 2022-2025 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $371.73 | 2023-2024 | Quviviq |
| Alkermes, INC. | $240.85 | 2022-2024 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $180.43 | 2021-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $180.41 | 2021-2023 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $173.14 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $170.72 | 2025 | Fanapt |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $163.97 | 2021-2023 | Belsomra |
| Janssen Pharmaceuticals, INC | $162.58 | 2023-2025 | Invega Trinza, Invega Sustenna, Spravato |
| Almatica Pharma LLC | $160.67 | 2023-2025 | Loreev Xr |
| Owp Pharmaceuticals, INC. | $81.11 | 2021-2025 | Subvenite, Lamotrigine |
| Bausch Health US, LLC | $66.92 | 2022-2023 | Aplenzin, Wellbutrin |
| Avadel Cns Pharmaceuticals, LLC | $49.59 | 2024 | Lumryz |
| Noven Therapeutics, LLC | $43.41 | 2024 | Xelstrym |
| Collegium Pharmaceutical, INC. | $43.36 | 2025 | Jornay Pm |
| Harmony Biosciences LLC | $42.78 | 2022 | |
| Eisai INC. | $40.65 | 2021-2022 | |
| Neos Therapeutics, Lp | $25.00 | 2024 | Adzenys Xr-Odt |
| E.R. Squibb & Sons, L.L.C. | $24.53 | 2024 | Cobenfy |
| Neuronetics, INC. | $19.77 | 2023 | Neurostar Tms Therapy System |
| Braeburn INC. | $15.47 | 2024 | Brixadi |
| Sunovion Pharmaceuticals INC. | $14.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Sperling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.